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ABSTRACT
Germline mutations in SPRTN cause Ruijs–Aalfs syn-
drome (RJALS), a disorder characterized by genome
instability, progeria and early onset hepatocellular
carcinoma. Spartan, the protein encoded by SPRTN,
is a nuclear metalloprotease that is involved in the
repair of DNA–protein crosslinks (DPCs). Although
Sprtn hypomorphic mice recapitulate key progeroid
phenotypes of RJALS, whether this model express-
ing low amounts of Spartan is prone to DPC repair
defects and spontaneous tumors is unknown. Here,
we showed that the livers of Sprtn hypomorphic mice
accumulate DPCs containing Topoisomerase 1 cova-
lently linked to DNA. Furthermore, these mice exhib-
ited DNA damage, aneuploidy and spontaneous tu-
morigenesis in the liver. Collectively, these findings
provide evidence that partial loss of Spartan impairs
DPC repair and tumor suppression.
INTRODUCTION
Germline mutations in SPRTN cause Ruijs–Aalfs syn-
drome (RJALS), a human autosomal-recessive disorder
characterized by genome instability, progeria and early
onset hepatocellular carcinoma (1,2). Our previous work
demonstrated that, while complete knockout of Sprtn in
mice was embryonically lethal, Sprtn hypomorphic mice are
viable despite reduced Spartan expression (3). Sprtn hypo-
morphic mice, however, developed premature aging pheno-
types and chromosomal instability (3), thereby recapitulat-
ing some of the findings in RJALS patients. Currently, it is
unknown whether Sprtn insufficiency causes tumor suscep-
tibility in Sprtn hypomorphicmice andwhyRJALS patients
are particularly prone to liver tumors.
Spartan was initially identified as a regulator of transle-
sion synthesis (TLS), a specialized replication system that
utilizes low fidelity TLS polymerases to bypass certain
DNA lesions without their actual repair (4,5). Spartan lo-
calizes to DNA lesions through its PCNA-interacting pep-
tide motif and UBZ4, a zinc-finger ubiquitin-binding do-
main in the C-terminus (6–12). Consistent with the role of
Spartan in TLS regulation, bypass of UV-induced DNA le-
sions was impaired in mouse embryonic fibroblasts (MEFs)
after Sprtn knockout (3). However, Sprtn knockout MEFs
develop even more severe phenotypes, including incom-
plete DNA replication, accumulation of abnormal chromo-
somes and cell death (3), suggesting that Spartan may have
TLS-independent functions. Consistent with this possibil-
ity, S. cerevisiae Wss1, which has a similar domain struc-
ture to Spartan, plays a role in the repair of DNA–protein
crosslinks (DPCs) (13,14), which are toxic DNA lesions
that block DNA replication and transcription and cause
genome instability (15–19). Accordingly, the similarity be-
tween Wss1 and Spartan raised the possibility that Spartan
might also participate in DPC repair.
Indeed, while this manuscript was in preparation, four
studies implicated Spartan in DPC repair (20–23). These
studies found that Spartan is a DNA-dependent metallo-
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protease that prevents accumulation of DPCs (20–23) and
a constitutive component of the replication machinery that
repairs DPCs in a DNA replication-coupled manner (21).
These findings, which are reminiscent of the replication-
coupled DPC repair previously reported in Xenopus egg ex-
tracts (24), clearly demonstrate the role of proteolytic events
in DPC repair. The physiological relevance of this protease-
mediated DPC repair process, however, requires further in-
vestigation.
DPCs involving Topoisomerase 1 (Top1) have been pro-
posed as one of the substrates of Spartan in human cells
(21). Top1 is an essential and abundant enzyme that re-
lieves DNA torsional strain during DNA replication and
transcription (25–27). Top1 cuts one strand of DNA, al-
lows rotation around the intact strand and then religates the
single-strand break (28). When re-ligation is blocked by ad-
jacent DNA lesions or by chemotherapeutic agents such as
camptothecin (CPT), Top1 is trapped as a covalent adduct
between the 3′ end of the nicked DNA and the Top1 active
site tyrosine. Commonly referred to as a Top1 cleavage com-
plex (Top1cc), this bulky DPC can block advancing replica-
tion forks, ultimately resulting in toxic DNA damage such
as DNA double-strand breaks and cell death (16–18,29).
Top1ccs can be repaired by a mechanism involving tyrosyl-
DNAphosphodiesterase 1 (Tdp1), which hydrolyzes the co-
valent bond between the Top1 catalytic tyrosine and the
DNA (29,30). The fact that a cell expresses specialized en-
zymes for repairing Top1ccs highlights the importance of
their repair. It is, therefore, crucial to understand the role of
Spartan in Top1cc repair in tissues as well as isolated cells.
In this study, we investigate whether Sprtn insufficiency
predisposes mice to tumor formation, particularly in the
liver. We also study the function of Spartan in the repair of
DPCs, especially Top1ccs, in mouse cells and tissues. Our
findings identify Spartan as a component of Top1cc repair
in mice, demonstrate its role as a tumor suppressor and link
Spartan deficiency with Top1cc accumulation and tumori-
genesis in hepatocytes.
MATERIALS AND METHODS
Sprtn-targeted mice and analyses of tumorigenesis
Sprtn hypomorphic mice (SprtnH/H) have been described
previously (3). Mice were euthanized by carbon dioxide
inhalation and all major organs were screened for spon-
taneous overt tumors. For histology analysis of liver tu-
mors, formalin-fixed paraffin-embedded tumor samples
were stained with hematoxylin and eosin and examined by
a mouse pathologist. All of the animal procedures were ap-
proved by Mayo Clinic Institutional Animal Care and Use
Committee.
Cell culture
SprtnF/F; Cre-ERT2 MEFs were described earlier (3).
SprtnH/– MEFs were generated as described previously
(3) and immortalized by retroviral expression of SV40 T-
antigen (31). MEFs were cultured in Dulbecco’s modified
Eagle medium supplemented with 10% fetal bovine serum.
SprtnF/F; Cre-ERT2 MEFs were treated for 2 days with 2
M 4-hydroxytamoxifen (4-OHT) dissolved in methanol
(MeOH) to induce Cre-mediated conversion of the floxed
allele to the knockout allele (3). In parallel, MEFs were
treated with the same amount of MeOH as a vehicle con-
trol.
Plasmids, RNA interference and viral infection
Complementary DNA fragments encoding wild-type or
the E112A mutant of human Spartan (8) were expressed
using the retroviral vector pMSCV-puro. Wild-type hu-
man Spartan (full-length) was also expressed with a C-
terminal 3xFlag tag using pMSCV-puro. The SprT domain
of human Spartan (amino acids 1–219) (8) was expressed
with a C-terminal 3xFlag/2xNLS tag using the retrovi-
ral vector pBabe-puro. For stable knockdown of Tdp1, a
short hairpin RNA (shRNA) against Tdp1 (shTdp1) or
a non-targeting shRNA (shControl) was expressed using
the lentiviral vector pLKO.1-puro. The shRNA sequences
were: shControl, 5′-CAACAAGAUGAAGAGCACCAA-
3′ and shTdp1, 5′-UAAAGUCCUGCACCCGUACAG-3′.
Knockdown of Tdp1 was confirmed by quantitative reverse
transcription-PCR. Retroviruses and lentiviruses were pro-
duced by cotransfection of viral and packaging plasmids in
the human embryonic kidney cell line 293T (ATCC, CRL-
11268). Cells were infected with virus-containing media in
the presence of 2 g ml−1 polybrene and selected with 3 g
ml−1 puromycin (Sigma).
Quantitative reverse transcription-PCR (qRT-PCR)
Total RNA was purified from cells using an RNeasy Kit
(Qiagen) and cDNAwas generated using oligo(dT) primers
and SuperScript III (Invitrogen) according to the supplier’s
instructions. qPCR was performed in triplicate for each
sample using a CFX96 PCR machine (Bio-Rad) and iTaq
Universal SYBR Green Supermix (Bio-Rad). The follow-
ing primers were used:Tdp1, forward primer (5′-TGGACG
CTT TCA AGG AAG TC-3′) and reverse primer (5′-CCG
ATGCTTGAGAACTGACC-3′);Gapdh, forward primer
(5′-AGA ACA TCA TCC CTG CAT CC-3′) and reverse
primer (5′-CAC ATT GGG GGT AGG AAC AC-3′); and
Sprtn, forward primer (5′-GGACCTTGTAGAGACTCT
TTT G-3′) and reverse primer (5′-CCT CAT CAT GGA
AAG TGT GG-3′) (3). Sprtn and Tdp1 mRNA levels were
normalized to Gapdh.
Immunofluorescence and microscopy
Experiments were performed as described previously (32).
Briefly, cells were fixed with 4% paraformaldehyde for 15
min at 4◦C, permeabilized for 15 min with 0.25% Triton
X-100 at 4◦C, and treated with 1% sodium dodecyl sul-
phate (SDS) for 5 min at room temperature. Cells were then
washed five times with wash buffer (0.1% Triton X-100,
0.1% bovine serum albumin (BSA) in phosphate buffered
saline (PBS), blocked in 10% milk in 150 mM NaCl and
10 mM Tris-HCl (pH 7.4) and incubated with primary
antibodies diluted in 5% normal goat serum overnight at
4◦C. Rabbit anti-H2AX was from Active motif (#39117,
1:750) and mouse anti-Top1cc (1:100) was reported previ-
ously (32). After washing five times with wash buffer, cells
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were stained with Alexa Fluor 488-conjugated (for Top1cc)
or Alexa Fluor 568-conjugated (for H2AX) secondary
antibodies (1:1000, Invitrogen) diluted in 5% normal goat
serum for 1 h at room temperature. Cells were washed with
wash buffer six times, stained with 0.1 g ml−1 DAPI (for
MEFs) or 1 g ml−1 Hoechst 33258 (for tissue samples) in
PBS and mounted with SlowFade Gold (Invitrogen). Im-
ages were captured using a LSM 710 scanning confocal mi-
croscope with a 100× objective and processed using the Im-
ageJ software and Adobe Photoshop CS5.
For immunostaining of tissues, fresh tissue samples
were embedded in optimal cutting temperature compound,
frozen in methylbutane at −80◦C, sectioned onto slides us-
ing a cryostat and immediately fixed with 4% paraformalde-
hyde for 15 min at 4◦C. Using the procedures described
above for tissue culture cells, the cells were then permeabi-
lized, treated with SDS and immunostained.
Clonogenic survival assays
For drug sensitivity assays, 500 cells were seeded per well
in triplicate into 6-well plates and cultured in the pres-
ence of various drugs. Drug-containing media were replen-
ished every other day and cells were cultured for six days.
After staining with Coomassie Blue, colonies with more
than 50 cells were counted manually (33). Drugs used in
clonogenic assays were: camptothecin (Sigma), etoposide
(Sigma), PARP inhibitor MK-4827 (ChemieTek) and 5-
aza-2′-deoxycytidine (Sigma).
Flow cytometry
Analyses of DNA content were performed as described pre-
viously (3). In brief, cells were harvested and fixed by incu-
bation in 70% ethanol overnight at −20◦C. After incuba-
tion with 50 g ml−1 propidium iodide, 10 g ml−1 RNase
A, 0.05% Nonidet P-40 for 30 min, cells were analyzed by
flow cytometry using a FACS Canto II (BD Biosciences).
Percentages of the cell-cycle phases were calculated using
ModFit LT (Verity Software House).
DNA fiber assays
Bypass ofUV-inducedDNA lesions was examined byDNA
fiber assays as described previously (3).
Nuclei isolation from tissues and Western blotting
Isolation of nuclei from mouse tissues was performed us-
ing a previously described method (34). Briefly, fresh tissues
were rinsed with STMbuffer (250mM sucrose, 50mMTris-
HCl (pH 7.4), 5 mMMgSO4), minced and homogenized in
STM buffer with freshly added 1 mMphenylmethylsulfonyl
fluoride (PMSF) (STM/PMSF). After filtering, sedimenta-
tion (800 × g for 15 min), and washing with STM/PMSF
buffer, the nuclei were resuspended in DSM (2.1 M sucrose,
50 mM Tris-HCl (pH 7.4), 5 mM MgSO4)/PMSF buffer,
layered over cushions of the same buffer and centrifuged
for 60 min at 20 000 rpm. The nuclei were resuspended in
STM/PMSF buffer, layered again over DSM/PMSF buffer
and sedimented for another 30 min.
Isolated nuclei were solubilized in alkylation buffer (6 M
guanidine hydrochloride, 250 mM Tris-HCl (pH 8.5), 10
mMEDTA) supplemented with 1 mMPMSF and 1% (v/v)
2-mercaptoethanol, sonicated, reacted with iodoacetamide
and dialyzed sequentially into 4 M urea and 0.1% SDS
as previously described (35). After lyophilization, samples
were resuspended in SDS sample buffer (4M urea, 2% SDS,
62.5 mM Tris-HCl (pH 6.8) and 1 mM EDTA) and heated
to 65◦C for 20 min. Aliquots containing 20 g protein were
separated by sodium dodecylsulphate-polyacrylamide gel
electrophoresis (SDS-PAGE), transferred to nitrocellulose
membranes and probed with antibodies. Anti-Top1 (C-21)
antibody was a gift from Y-C Cheng (Yale University, New
Haven, CT, USA). Antibodies against Histone H1 (#61201,
1:5000) were from Active Motif.
To analyze Spartan protein levels in MEFs, cells were
lysed in NP-40 lysis buffer (50 mM Tris-HCl pH 7.4, 150
mMNaCl, 0.1% Nonidet P-40, 5 mMEDTA, 50 mMNaF,
1 mM Na3VO4, 10% Glycerol) supplemented with pro-
tease inhibitor mix (Sigma). Supernatants containing sol-
ubilized proteins were recovered after centrifugation (12
000 rpm, 15 min). Aliquots containing 30 g of protein
were separated by SDS-PAGE, transferred to nitrocellu-
lose membranes and probed with antibodies. Anti-Flag
(#F1804, 1:2000) and anti--actin (#A5316, 1:5000) an-
tibodies were purchased from Sigma. Mouse anti-human
Spartan antibodies were reported previously (9). Antibod-
ies against POLD1 (#sc-17 777, 1:250) and PCNA (#sc-56,
1:2000) were from Santa Cruz Biotechnology. Anti-POLD3
(#A301-244A, 1:1000) and anti-H2A (#07-146, 1:2000) an-
tibodies were from Bethyl Laboratory and EMDMillipore,
respectively.
CPT- induced Top1 degradation assay
CPT-induced Top1 degradation was assayed using a pre-
viously described method (36,37) with slight modification.
Briefly, MEFs grown in 100-mm tissue culture plates were
treated with CPT as indicated in the figure legend, incu-
bated for 30 min in drug-free medium, lysed in alkaline ly-
sis buffer (200 mMNaOH, 2 mMEDTA), neutralized with
1.5 M Tris-HCl, pH 8.0 and mixed with 10 × S7 nuclease
buffer (50 mMMgCl2, 50 mMCaCl2, 5 mM dithiothreitol,
1 mMEDTA and a protease inhibitor mixture). Cell lysates
were incubated with 100 units of staphylococcal S7 nucle-
ase (Sigma) on ice for 20 min, which allowed Top1 release
fromDNA.Reactionswere terminated by the addition of 20
mMEGTA.After a brief sonication, aliquots containing 12
g of protein were separated by SDS-PAGE, transferred to
nitrocellulose membranes and probed with anti-Top1 anti-
body (C-21, BD Biosciences #556597, 1:2000) and anti--
actin antibody (#A5316, Sigma, 1:5000).
iPOND (Isolation of proteins on nascent DNA)
iPOND experiments were performed as described previ-
ously (38). Briefly, cells were treated with 10 M EdU (In-
vitrogen) for 15 or 20min to label nascentDNA, and chased
with 10 M thymidine for 10 and 30 min. Harvested cells
were fixed with 1% formaldehyde for 20 min, permeabi-
lized for 30 min with 0.25% Triton X-100 at room tempera-
ture followed by 90 min of click reaction, in which biotin is
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conjugated to EdU in EdU-labeled DNA. Cells were then
lysed in RIPA lysis buffer (50 mM Tris-HCl pH 7.4, 150
mM NaCl, 1% Nonidet P-40, 0.1% SDS, 1 mM EDTA,
0.5% sodium deoxycholate) supplemented with protease in-
hibitor mix and PMSF followed by sonication (20 s ON,
40 s OFF for 4 cycles). Supernatants containing solubilized
DNA-protein complexes were recovered after centrifuga-
tion (12 000 rpm, 15min). To purify the EdU-labeledDNA–
protein complexes, recovered samples were incubated with
streptavidin–agarose beads overnight at 4◦C. After washing
the beads once with lysis buffer, once with 1 M NaCl, once
with PBS and twice with lysis buffer, the precipitated pro-
teins in DNA–protein complexes were eluted by boiling in
2xLDS (Lithium dodecyl sulfate) sample buffer and ana-
lyzed by Western blotting.
ICE assays
In vivo complexing of enzyme (ICE) experiments for de-
tecting Top1cc were performed as described (32). Briefly,
MEFs grown in 150-mm tissue culture plates were lysed
in lysis buffer (1% (w/v) sarkosyl in 1 M Tris-HCl pH
8.0, 0.1 M EDTA), layered on top of a CsCl gradient and
sedimented at 31 000 rpm for 21 h at 22◦C to separate
DNA–protein complexes from free proteins. Fractions (0.5
ml) were collected from the bottom of the gradients. Us-
ing a slot blotting apparatus, 0.05 ml aliquots from each
fraction were immobilized onto nitrocellulose membranes
and probed with anti-Top1 antibody (C-21, BDBiosciences
#556597, 1:2000) and anti-PCNA antibody (#sc-56, Santa
Cruz Biotechnology, 1:2000).
Fluorescence in situ hybridization (FISH)
Interphase FISH analysis was performed as previously de-
scribed (39). Briefly, tissues were cut into small pieces and
minced in 1 ml of PBS containing 0.5% BSA and 2 mM
EDTA using a gentleMACS Dissociator (Miltenyi Biotec).
Twenty microliters of 7 mg ml−1 Liberase TM (Roche,
#05401127001) were added, and the cell suspension was in-
cubated at 37◦C for 30 min. After subsequent dissociation
using gentleMACS Dissociator, cells were collected with 5
ml PBS and separated from undigested tissues using a 70-
m cell strainer. Cells were then collected by centrifuga-
tion (1000 rpm, 5 min) and resuspended in 1 ml of PBS
containing 0.5% BSA and 2 mMEDTA. Following suspen-
sion, 40 l of methanol:glacial acetic acid (3:1) fixative was
added. After two washes with 5 ml of fixative, cells were
resuspended in 50–100 l fixative, dropped onto positively
charged microscope slides and labeled using FISH probes
for chromosomes 4 and 7. At least 100 cells were analyzed
per sample.
Statistics
GraphPad 5 Prism software was used to graph the data. Sta-
tistical significance was determined either by a two-tailed
unpaired t-test or a Fisher’s exact test, where specified. All
graphs are indicated with the significance as follows: *P <
0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
RESULTS
The SprT domain of Spartan is sufficient to support the nor-
mal cell cycle, but not lesion bypass.
Conditional Sprtn knockout inMEFs causes impaired TLS
of UV-induced DNA lesions and accumulation in late S
and G2 phases of the cell cycle (3). Whether the TLS defi-
ciency causes the observed cell-cycle defects in Sprtn knock-
out cells is not known. To address this question, we com-
pared the ability of full-length Spartan and the N-terminal
half of Spartan, which contains the SprT domain, to restore
TLS and cell-cycle progression in Sprtn knockout MEFs
(Figure 1A). Ectopic expression of full-length human Spar-
tan, but not the isolated SprT domain, restored TLS of UV-
induced lesions in Sprtn knockout cells (Figure 1A and B
and Supplementary Figure S1), indicating the necessity of
the C-terminal half for the TLS function of Spartan (Fig-
ure 1A). In contrast, expression of the N-terminal half of
Spartan relieved arrest of cells in late S/G2 and restored
the normal cell-cycle distribution (Figure 1C). These results
indicate that the cell-cycle function of Spartan is separa-
ble from the TLS function, and suggest that Spartan has
a TLS-independent function that is critical for completing
DNA replication in S phase. Consistent with the role of
Spartan in DNA replication, iPOND, a method that an-
alyzes proteins isolated with nascent DNA (38), revealed
that Spartan localizes at sites of DNA replication and trav-
els with replicationmachinery components such as POLD1,
POLD3 (subunits of DNA polymerase ) and PCNA (Fig-
ure 1D). Given that the SprT domain was sufficient for nor-
mal cell-cycle progression, we next asked whether the SprT
domain alone can localize to replication forks. Notably, the
isolated SprT domain, like full-length Spartan, was recov-
ered with nascent DNA (Figure 1E), indicating the suffi-
ciency of the SprT domain for localization to replication
forks.
Reduced Sprtn expression sensitizes cells to camptothecin
In exploring the TLS-independent function of Spartan, we
turned our attention to the recent report that Wss1, a Spar-
tan ortholog in S. cerevisiae, plays a role in the repair of
DPCs, including Top1ccs (13,40). To assess whether Spar-
tan plays a similar role in Top1cc repair in vertebrates, we
examined the possibility that Spartan counteracts the toxic
effect of Top1ccs induced by CPT in mammalian cells and
compared the effect to knockdown of Tdp1, a phosphodi-
esterase implicated in enzymatic removal of Top1ccs. Be-
cause Sprtn knockout is lethal in MEFs (3), we used Sprtn
hypomorphic MEFs (SprtnH/–), which express reduced lev-
els of Spartan but exhibit a normal cell-cycle distribution
(3) (Supplementary Figure S2A and S2B). SprtnH/– MEFs
displayed increased CPT sensitivity compared to Sprtn+/+
MEFs (Figure 2A), suggesting a possible role for Spartan
in the repair of Top1ccs. Moreover, the degree of sensitiza-
tion to CPT in SprtnH/– MEFs was similar to that of Tdp1
knockdown in Sprtn+/+ MEFs, indicating that Spartan is as
important as Tdp1 in counteracting Top1cc toxicity.
In addition to Top1cc processing by Tdp1, proteasome-
dependent Top1 degradation has been reported
(36,37,41,42). To assess whether Spartan participates
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Figure 1. The SprT domain is sufficient to suppress the cell-cycle defects, but not the lesion bypass deficiency, in Sprtn knockout cells. (A) Schematic
representation of full-length and truncated Spartan proteins used in this study. The truncated Spartan mutant, denoted as SprT, contains the SprT do-
main but lacks the C-terminal half. SprT, a zinc metalloprotease-like domain; SHP, a p97/VCP-interacting motif; PIP, PCNA-interacting peptide; UBZ4,
ubiquitin-binding zinc-finger 4. (B) (Upper panel) Schematic representation of DNA fiber assays. To visualize ongoing replication, mouse embryonic fi-
broblasts (MEFs) treated withMeOH or 4-OHT for 48 h were sequentially labeled with IdU and CldU with or without UV irradiation (40 J m−2) between
the labeling. (Lower panel) DNA fiber assays were performed in SprtnF/F; Cre-ERT2 MEFs expressing full-length human Spartan (FL) or the SprT do-
main only (amino acids 1–219). Distribution of replication forks at different CldU/IdU ratios is shown. At least 100 fibers were scored for each sample.
Horizontal red lines indicate median values. (C) Cell-cycle profiling of SprtnF/F; Cre-ERT2 MEFs expressing full-length human Spartan (FL) or the SprT
domain only (amino acids 1–219). Cells were treated with MeOH or 4-OHT for 48 h, stained with PI and analyzed by flow cytometry. (D) Isolation of
proteins on nascent DNA (iPOND) assays showing the localization of Spartan at replication forks. 293T cells were pulsed with EdU for 15 min and then
chased with thymidine for 10 and 30 min. Eluted proteins were separated by sodium dodecylsulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and
immunoblotted for the indicated proteins. PCNA, POLD1 and POLD3 are shown as controls for replisome proteins that are enriched only at replication
forks. Histone H2A is shown as a chromatin protein that is not enriched at replication forks. (E) iPOND assays showing that the isolated SprT domain of
Spartan can localized at the fork. iPOND was performed in 293T cells expressing full-length human Spartan (FL) or the SprT domain only after pulse
labeling with EdU for 20 min. Proteins at EdU-labeled nascent DNA were isolated and assessed using Western blotting. PCNA is shown as a control for
replisome protein.
in this proteasomal pathway, Spartan-proficient and
conditional Sprtn-knockout MEFs were treated for up
to 4 h with 25 M CPT (36,37,41,42) and subjected to
immunoblotting for Top1. Top1 degradation was observed
only at high CPT concentrations and was not altered
in Sprtn–/– MEFs (Supplementary Figure S2C), arguing
against a role for Spartan in CPT-induced proteasomal
degradation of Top1.
In contrast to CPT, no increases in sensitivity were
observed in SprtnH/– MEFs treated with the following
DPC-forming drugs: etoposide (which traps Topoisomerase
2-DNA covalent complexes), MK-4827 (which enhances
poly(ADP-ribose) polymerase 1-DNA interactions, includ-
ing covalent adducts) and 5-aza-2′-deoxycytidine (which
causes DNA methyltransferase-DNA covalent adducts)
(43,44) (Supplementary Figure S2D–F). These results in-
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Figure 2. SprtnH/− MEFs exhibit increased sensitivity to camptothecin and Sprtn knockout causes accumulation of Top1ccs in MEFs. (A) Clonogenic
survival assays. Sprtn+/+ and SprtnH/− MEFs, with or without Tdp1 knockdown, were cultured in the presence of the indicated camptothecin (CPT)
concentration for 6 days while drug-containing media were replenished every other day. Cells were stained with Coomassie Blue and colonies with more
than 50 cells were counted. Values are mean ± s.e.m. of three independent experiments. *P < 0.05; **P < 0.01; ***P < 0.001 (two-tailed unpaired t-
test) relative to Sprtn+/+ shControl. The inset shows qPCR analyses of Tdp1 mRNA levels in the indicated MEFs. Values were normalized to Gapdh
and presented relative to Sprtn+/+ shControl. (B) Detection of Top1ccs by in vivo complexing of enzyme (ICE) assays. SprtnF/F; Cre-ERT2 MEFs were
treated with MeOH or 4-OHT for 48 h and Top1ccs were separated from free Top1 by cesium chloride gradients. Fractions (#1-8) were deposited onto
nitrocellulose membranes and probed with antibody against Top1 (left) or PCNA (right). Cells treated with 5 M CPT for 1 h are shown as a positive
control for Top1ccs. (C) Top1cc focus formation. The indicated MEFs treated with MeOH or 4-OHT for 48 h were stained with anti-Top1cc to detect
Top1cc accumulation. DNA was co-stained with DAPI to visualize nuclei. (D) Quantitation of Top1cc foci. Experiments were performed as in C. At least
100 cells were scored for Top1cc foci and percentages of cells with 8 or more foci are shown. Values are mean ± s.e.m. of three independent experiments.
*P < 0.05; ***P < 0.001 (two-tailed unpaired t-test) relative to the MeOH-treated shControl samples.
dicate that Spartan is particularly important in combating
toxic lesions generated by Top1 poisons.
Spartan loss causes accumulation of Top1ccs
To test whether Spartan participates in the repair of
Top1ccs, we examined the accumulation of Top1ccs in
MEFs after Sprtn deletion. In initial experiments, we used
ICE assays, which separate covalent protein–DNA com-
plexes from free proteins on CsCl gradients. These as-
says detected increased Top1, but not PCNA, in DNA-
containing gradient fractions after the Sprtn gene was con-
ditionally deleted in MEFs (Figure 2B). These results indi-
cate that Spartan loss increases the covalent binding of Top1
to DNA.
To verify this finding using another experimental ap-
proach, we stained MEFs with an antibody that specif-
ically detects Top1ccs (32) (Supplementary Figure S3A).
Sprtn knockout resulted in punctate staining of nuclei with
this antibody (Figure 2C and D), a pattern similar to that
observed with CPT (32). In agreement with the role of
Tdp1 in Top1cc repair (29), Tdp1 knockdown also caused
increased accumulation of Top1ccs in Spartan-proficient
MEFs (Figure 2C and D and Supplementary Figure S3B).
Interestingly, depletion of Tdp1 in Sprtn knockout cells did
not cause further Top1cc accumulation compared to Sprtn
knockout alone (Figure 2C and D). Collectively, these re-
sults suggest that Spartan plays an important role in the re-
pair of Top1ccs in a pathway that may also involve Tdp1.
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The SprT domain is necessary and sufficient for preventing
Top1cc accumulation
Spartan contains a metalloprotease domain SprT (Figure
1A). To test whether the SprT domain plays a role in the re-
pair of Top1ccs, we expressed either wild-type human Spar-
tan or SpartanE112A, which harbors a point mutation in the
SprT metalloprotease active site (8), in conditional Sprtn
knockout MEFs (Supplementary Figure S4). Ectopic ex-
pression of wild-type human Spartan, but not SpartanE112A,
suppressed the accumulation of Top1ccs in Sprtn–/– cells
(Figure 3A and B), suggesting a role for catalytically active
metalloprotease in Top1cc repair. To further evaluate the
role of the SprT domain, we next asked whether the SprT
domain itself is sufficient to suppress Top1cc accumulation.
Notably, introduction of just the SprT domain suppressed
Top1cc accumulation in Sprtn–/– cells as effectively as wild-
type Spartan (Figure 3C and D and Supplementary Fig-
ure S1). These results demonstrate that the metalloprotease
SprT domain alone is sufficient for Top1cc repair, and sug-
gest that a catalytically active SprT domain is necessary for
Top1cc removal.
Accumulation of Top1ccs in the liver of SprtnH/H mice
We next asked whether Top1cc lesions accumulate in Sprtn
hypomorphic mouse tissues. For these studies, we focused
on the liver because (i) humans with germline Sprtn muta-
tions develop hepatocellular carcinoma (1,2), implying that
the liver is specifically affected by Spartan deficiency; and
(ii) Top1 (∼100 kDa) is highly expressed in nuclei from
the mouse liver compared to other tissues (Figure 4A). As
shown in Figure 4B, Top1ccs were readily detected in the liv-
ers of 4-month-old SprtnH/H mice, indicating that SprtnH/H
livers exhibit impaired Top1cc repair at an early age. In con-
trast, few if any Top1cc foci were observed in other tissues
including brain, thymus, spleen and kidney from Sprtn+/+
and SprtnH/H mice (Figure 4C), consistent with lower Top1
expression in these tissues compared to the liver (Figure
4A). In addition, 4-month-old SprtnH/H mice displayed in-
creased levels of H2AX foci, a DNA damage marker, in
the liver but not in other tissues (Figure 4D and E). These
findings suggest that Sprtn insufficiency causes Top1cc ac-
cumulation in the liver at an early age, accompanied by
DNAdamage. Collectively, these results inmouse liver (Fig-
ure 4) identify a physiological context in which Spartan
plays a rate-limiting role in Top1cc repair.
Sprtn insufficiency drives tumorigenesis in mice, particularly
in the liver
Because cells isolated from Sprtn hypomorphic mice exhib-
ited chromosome instability (3), we next examined whether
the livers of these mice have abnormal numbers of chromo-
somes. FISH analyses revealed that livers in SprtnH/H mice
are more aneuploid than livers from Sprtn+/+ mice (Figure
5A and B). Given that increased aneuploidy and chromo-
some instability have been commonly linked with cancer
predisposition (45–48), we also asked whether Sprtn insuf-
ficiency renders mice more prone to tumorigenesis. To ad-
dress this question, we established cohorts of Sprtn+/+ and
SprtnH/H mice and screened them for overt tumor formation
at 22–25 months of age. Nearly 70% of SprtnH/H mice dis-
played spontaneous tumors, a significant increase in the tu-
mor incidence from 25% in Sprtn+/+ mice (Figure 5C). This
result indicates that reduced Spartan expression promotes
spontaneous tumor formation in mice. Notably, the types
of tumors were different in Sprtn+/+ and SprtnH/H mice
(Figure 5D). The livers of SprtnH/H mice, which showed
persistent accumulation of Top1ccs (Supplementary Figure
S5A and S5B), were the primary site of tumor formation,
although the size and number of tumors per liver varied
among themice (Figure 5D and E). Histology of the tumors
indicated that most of the liver tumors were hepatic ade-
nomas, characterized by nodular collections of hepatocytes
with bland cytology and normal trabecular architecture. In
one of eight nodules examined, liver plates werewidened (3–
4 cells thick) and hepatocytes were pleomorphic, supporting
a diagnosis of hepatocellular carcinoma (Figure 5F). Col-
lectively, these results indicate that Sprtn insufficiency pre-
disposes mice to spontaneous tumorigenesis, particularly in
the liver.
DISCUSSION
Our previous study demonstrated that reduced Spartan lev-
els in mice caused premature aging phenotypes, includ-
ing lordokyphosis, cataracts and senescence (3). Here, we
demonstrate that Sprtn hypomorphic mice are also prone to
spontaneous tumorigenesis as they age further (Figure 5C).
Both premature aging and the cancer susceptibility seen in
the Sprtn hypomorphic mice recapitulate phenotypes ob-
served in patients with RJALS. Consistent with the notion
that RJALS is a genome instability syndrome, DNA dam-
age and abnormal numbers of chromosomes are observed
in Sprtn hypomorphic mice (3). To our knowledge these re-
sults provide the first evidence that Sprtn insufficiency in
mice recapitulates all of the major phenotypes of RJALS
in humans.
Our current study also identifies Top1cc as a DPC le-
sion that accumulates in the liver when Spartan levels are
reduced (Figure 4B and C and Supplementary Figure S5A
and S5B). Coupled with the observation that conditional
Sprtn knockout in MEFs also causes Top1cc accumulation
(Figure 2B–D), which is consistent with a role for Spartan
in Top1cc repair, our results in mice support and extend the
recent report that Spartan repairs DPCs, including Top1cc,
in cultured cell lines (21). Importantly, we demonstrate that
Sprtn insufficiency in mice causes Top1cc accumulation in
the absence of Top1 poisons (Figure 4B and C and Sup-
plementary Figure S5A and S5B), suggesting that Spartan
plays a critical role in keeping the Top1cc levels low even
in mice that have not been treated with Top1 poisons. Our
findings are consistent with the possibility that DPC repair
defects contribute to the phenotypes observed in Sprtn hy-
pomorphic mice and RJALS patients.
The liver is the predominant site of tumor formation in
RJALS patients and Sprtn hypomorphic mice (Figure 5D)
(1,2). While the mechanism underlying the tissue specificity
remains unknown, it is noteworthy that total Top1 protein
levels are particularly high in liver nuclei (Figure 4A), rais-
ing the possibility that more Top1cc will form in this tis-
sue during normal Top1-mediated catalysis. Moreover, we
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Figure 3. The SprT domain of Spartan is necessary and sufficient to suppress Top1cc accumulation in Sprtn knockout MEFs. (A) Top1cc focus formation
in SprtnF/F; Cre-ERT2 MEFs expressing wild-type human Spartan or the E112A mutant. Cells were treated with MeOH or 4-OHT for 48 h, and stained
with anti-Top1cc antibodies and DAPI. (B) Quantitation of cells containing Top1cc foci. At least 100 cells were scored for Top1cc foci and percentages of
cells with 8 or more foci are shown. Values are mean ± s.e.m. of four independent experiments. (C) Top1cc focus formation in SprtnF/F; Cre-ERT2 MEFs
expressing full-length (FL) human Spartan or the SprT domain (amino acids 1–219). Cells were treated as in A. (D) Quantitation of cells containing Top1cc
foci. Cells were scored as in B. Values are mean ± s.e.m. of three independent experiments. *P < 0.05; **P < 0.01; ****P < 0.0001 (two-tailed unpaired
t-test).
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Figure 4. The livers of SprtnH/H mice exhibit increased accumulation of Top1ccs. (A) Expression levels of nuclear Top1 in the indicated tissues of 10-
month-old female Sprtn+/+ mice as assessed by anti-Top1 Western blotting. Histone H1 is shown as a loading control. (B) Immunohistochemistry of
Top1ccs in the liver of 4-month-old mice. Cryosections of the liver from Sprtn+/+ and SprtnH/H mice were stained with anti-Top1cc. DNAwas stained with
Hoechst to visualize nuclei. (C) Quantitation of cells containing Top1cc foci in the indicated tissues of 4-month-old mice. At least 100 cells were scored for
Top1cc foci in Sprtn+/+ and SprtnH/H mice. Percentages of cells with 10 or more foci are shown. Values are mean ± s.e.m. (n = 3). No cells were scored as
positive for Top1cc foci in the thymus, spleen and kidney. (D) Immunohistochemistry of H2AX in the liver of 4-month-old mice. Cryosections of the liver
from Sprtn+/+ and SprtnH/H mice were stained with anti-H2AX. DNA was stained with Hoechst to visualize nuclei. (E) Quantitation of cells containing
H2AX foci in the indicated tissues of 4-month-old mice. At least 100 cells were scored for H2AX foci and percentages of cells with 10 or more foci are
shown. Values are mean ± s.e.m. (n= 3). No cells were scored as positive for H2AX foci in the spleen. *P< 0.05; **P< 0.01 (two-tailed unpaired t-test).
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Figure 5. Sprtn insufficiency promotes spontaneous tumorigenesis. (A) Images of interphase fluorescence in situ hybridization (FISH) for chromosomes
4 (red) and 7 (green). Liver cells from 22-month-old male Sprtn+/+ and SprtnH/H mice are shown. Because normal liver cells can be polyploid, only cells
that contain odd numbers of chromosomes 4 or 7 were scored as aneuploid. Note that liver cells from Sprtn+/+ mice have normal ploidy, whereas liver
cells from SprtnH/H mice exhibit aneuploidy with three copies of chromosomes 4. (B) Quantitation of aneuploidy in liver cells from Sprtn+/+ and SprtnH/H
mice. Experiments were performed as in A. At least 100 cells were scored for aneuploidy and percentages of aneuploid cells are shown. Values are mean
± s.e.m. (n = 3). *P < 0.05; **P < 0.01; ***P < 0.001 (two-tailed unpaired t-test). (C) Spontaneous tumor incidence of 22- to 25-month old Sprtn+/+
and SprtnH/H mice. (Sprtn+/+, n = 24; SprtnH/H, n = 25). **P < 0.01 (Fisher’s exact test). (D) Spectrum of spontaneous tumor types in 22- to 25-month
old Sprtn+/+ and SprtnH/H mice. **P < 0.01 (Fisher’s exact test). (E) Images of spontaneous liver tumors in 22-month-old SprtnH/H mice. Tumors are
indicated by dotted yellow lines. (F) Hematoxylin and eosin-stained histological images of spontaneous liver tumors (hepatocellular carcinoma and hepatic
adenoma) from SprtnH/H mice. Dotted yellow lines indicate hepatic adenoma. Scale bars, 50 m.
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find that Top1ccs accumulate in the livers ofSprtn hypomor-
phic mice from an early age (Figure 4B and C). Given that
Top1ccs are mutagenic and genome destabilizing in yeast as
well as in mammalian cells (49–51), it is tempting to specu-
late that Top1cc-associated genomic instability might con-
tribute to tumor formation in the livers of Sprtn hypomor-
phic mice. In addition, given the recent finding that Spar-
tan promotes repair of formaldehyde-induced DPCs (20–
23), it is possible that formaldehyde-induced DPCs might
contribute to liver tumorigenesis as well. Because the liver is
the main organ that processes formaldehyde, Spartan might
play a particularly important role in the liver to combat
DPCs. Altogether, the liver appears to be more prone to
DPC accumulation and, therefore, specifically affected by
Spartan inactivation.
An undefined replication-coupled proteolytic event has
been described for DPC repair in Xenopus egg extracts, al-
though the protease remains unidentified (24). In this sys-
tem, replication fork collision with a DPC leads to DPC
proteolysis followed by TLS past the remaining peptide–
DNA lesion. Consistent with this model, a recent report
suggested that Spartan is a constitutive part of the repli-
cation machinery (Figure 1D) (21). Our experiments also
support this conclusion and extend it further by show-
ing that the isolated SprT domain localizes to replication
sites (Figure 1E). These data suggest that the SprT do-
main associates with the replication machinery indepen-
dently of the C-terminal PCNA-interacting peptide mo-
tif and UBZ4 domain, and the recently reported DNA-
binding sites (20,21,52). Consistent with this interpreta-
tion, our previous study identified interactions between the
Spartan SprT domain and DNA polymerase  (8). On
the other hand, a DNA replication-independent function
of Spartan has also been suggested in C. elegans and D.
melanogaster (20,53). Thus, it remains unclear whether the
Spartan-dependent DPC repair pathway is always coupled
with DNA replication. Nevertheless, the present findings
further support an emerging role for Spartan in the repair
of DPCs.
We also obtained additional insight into the mechanism
of Top1cc repair by Spartan using our conditional Sprtn-
knockout and Sprtn hypomorphic MEFs. First, we show
that the active site in the SprT protease domain is neces-
sary for repair (Figure 3A andB), and that the SprT domain
is sufficient for the Top1cc repair in vivo if nuclear localiza-
tion signals are attached (Figure 3C andD). Thus, although
the C-terminus of Spartan contributes to optimal protease
activity in vitro (20,21), that portion of the protein is dis-
pensable for the cell cycle and Top1cc repair in intact cells.
Residual protease activity of the SprT domain and its in-
trinsic affinity for the replication machinery might be suf-
ficient to allow DPC repair in vivo. Second, our data show
that Top1ccs do not accumulate further when Tdp1 was de-
pleted in Sprtn knockout cells (Figure 2C and D), support-
ing the recent notion that Spartan and Tdp1 may work in
the same Top1cc repair pathway (21). Third, we show that
cells with reduced Spartan expression are sensitive to CPT,
but not to other DPC-inducing drugs (Figure 2A and Sup-
plementary Figure S2D–F). This suggests that Spartanmay
not participate in the repair of all DPCs. However, recent
studies reported hypersensitivity of Spartan-depleted cells
and RJALS patient cells to etoposide (21,22). This discrep-
ancymight be explained if the Sprtn hypomorphic cells used
here expressed enough Spartan to repair etoposide-induced
DPCs but not Top1ccs. Nonetheless, our data suggest that
Top1ccs might be the predominant DPCs that depend on
Spartan for clearance. Finally, our data show that Spartan
does not participate in CPT-induced proteasomal degrada-
tion of Top1 (Supplementary Figure S2C). This suggests
that Spartan might be important for Top1cc repair when
Top1cc accumulation is under a certain threshold, whereas
the proteasome pathway becomes predominant when cells
accumulate extremely high levels of Top1cc after treatment
with CPT concentrations that are unachievable with clinical
drug exposures.
In conclusion, this study identifies Spartan as an impor-
tant factor in Top1cc repair, particularly in the liver and
shows that Spartan is a tumor suppressor. Future work will
determine the role of DPCs in premature aging and tumori-
genesis in Sprtn hypomorphic mice. Understanding the dif-
ferent functions of Spartan at the molecular level will also
help determine how failure to respond to various DNA le-
sions affects cell viability, progeria and cancer.
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Supplementary Data are available at NAR Online.
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